AXT-914

AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research[1][2].

Product Specifications

CAS Number

[717104-43-3]

UNSPSC

12352005

Target

CaSR; SARS-CoV

Related Pathways

Anti-infection; GPCR/G Protein

Field of Research

Infection; Endocrinology; Metabolic Disease

Smiles

O=C1N=C(C2=C(N1CC3=CC=C(C=C3)Br)C=CC(OCC#C)=C2)C4=CC=C(C(C)C)C=C4

Molecular Formula

C27H23BrN2O2

Molecular Weight

487.39

References & Citations

[1]Brun J, et al. Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals. Antiviral Res. 2025 May;237:106123. |[2]Letz S, et al. Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia. PLoS One. 2014 Dec 15;9 (12) :e115178.